Private placement in Cinclus Pharma Holding AB (SE) – SEK 241 million

Carnegie acted as financial adviser in Cinclus Pharma’s completion of a private placement of SEK 241 million. Cinclus Pharma is a clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium Competitive Acid Blocker (P-CAB), and is a fast-acting regulator of intragastric pH by a different mechanism of action than PPIs.
May 2022.